SI-BONE INC

Company Overview

SI‑BONE Inc. is a California‑based medical device company focused on products and instruments used in sacroiliac joint (SIJ) procedures and related surgical workflows. For Q2 2025 the company reported revenue of $48.6 million (up 21.7% year‑over‑year) and six‑month revenue of $95.9 million (up 23.2% YTD), driven by higher U.S. case volumes, expanded physician adoption (>3,600 trained) and greater ASC/OBL utilization (~30% of SIJ procedures). Gross margin remains high (~79.8%) while operating expenses have risen due to sales commissions, headcount and higher G&A (including stock‑based compensation); cash and marketable securities were $145.5M with $35.5M of outstanding debt. Management is investing in sales force expansion, instrument trays and inventory to support new product launches while noting reimbursement, regulatory and financing risks.

Executive Compensation Practices

Compensation at SI‑BONE is likely structured to emphasize commercial growth and clinical milestones: variable pay and commissions tied to revenue and procedure volume (sales commissions were explicitly noted) reward sales productivity and new physician adoption, while equity grants and stock‑based compensation appear to play a material role in G&A and retention for corporate and clinical talent. R&D is roughly 9% of revenue and progress on clinical programs (SILVIA, SAFFRON, STACI) creates natural long‑term incentive targets—executive LTI awards may be linked to regulatory/clinical readouts, reimbursement wins, and product launch success. Given the company’s stated cash runway and a term loan on the balance sheet, compensation mixes may lean on equity and milestone‑based incentives to conserve cash, while annual bonuses are likely tied to revenue, gross margin and working capital/operational efficiency metrics.

Insider Trading Considerations

Material, market‑moving events for SI‑BONE include quarterly results, clinical trial readouts/publications (e.g., SILVIA, SAFFRON, STACI), product launches and reimbursement or regulatory announcements; insiders trading around those events warrant close scrutiny. Seasonality (summer softness), inventory builds for new product families, and the company’s disclosure that additional financing could be required create windows where insider trades may precede or follow financing-related news. Expect typical governance safeguards—quarterly blackout periods, Section 16 short‑swing considerations for officers/directors, and frequent use of Rule 10b5‑1 plans—to be relevant; vested equity and option exercises can also drive insider sales for diversification, so watch timing relative to clinical milestones and earnings releases.